Inhibitor Therapeutics, Inc. (CBTE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Inhibitor Therapeutics, Inc. (CBTE) trades at $0.39. Inhibitor Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies. The company operates within the healthcare sector, specifically targeting medical solutions. Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for CBTE: CBTE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBTE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBTE: 1/1 perspectives are bearish.
How is this calculated? →Inhibitor Therapeutics, Inc. (CBTE) Healthcare & Pipeline Overview
Inhibitor Therapeutics, Inc. operates in the healthcare sector, focusing on pharmaceutical development. The company's business model centers around creating and potentially commercializing innovative therapies. Currently trading on the OTC market, Inhibitor Therapeutics faces unique challenges and opportunities compared to exchange-listed peers.
What Is the Investment Thesis for CBTE?
Investing in Inhibitor Therapeutics, Inc. presents a high-risk, high-reward scenario. The company's success hinges on its ability to successfully develop and commercialize its therapeutic pipeline. Key value drivers include the successful completion of clinical trials, regulatory approvals from bodies like the FDA, and the establishment of strategic partnerships for manufacturing and distribution. The company's current P/E ratio of -4.43 indicates it is not currently profitable. Growth catalysts include positive clinical trial data releases and potential breakthroughs in its research programs. However, potential investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and disclosure requirements. The company's high beta of 2.58 suggests significant volatility compared to the broader market.
Based on FMP financials and quantitative analysis
CBTE Key Highlights
- P/E ratio of -4.43, indicating the company is currently unprofitable.
- Beta of 2.58, suggesting high volatility compared to the overall market.
- Operates in the Medical - Pharmaceuticals industry, a sector known for high growth potential and regulatory scrutiny.
- Trades on the OTC market, which presents unique risks and opportunities compared to exchange-listed companies.
- No dividend yield, reflecting the company's focus on reinvesting earnings into research and development.
Who Are CBTE's Competitors?
CBTE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBTE's Key Strengths?
- Focus on innovative therapies.
- Potential for proprietary technologies.
- Dedicated research and development team.
What Are CBTE's Weaknesses?
- Limited financial resources.
- Dependence on successful clinical trials.
- OTC market listing.
What Could Drive CBTE Stock Higher?
- Clinical trial data releases for its therapeutic pipeline.
- Potential for strategic partnerships and collaborations.
- Regulatory approval process for its products.
What Are the Key Risks for CBTE?
- Insider selling — insiders were net sellers of roughly $3.0M recently.
- Unsuccessful clinical trials.
- Regulatory delays or rejections.
- Competition from larger pharmaceutical companies.
- Limited financial resources.
- OTC market listing risks.
What Are the Growth Opportunities for CBTE?
- Expansion into New Therapeutic Areas: Inhibitor Therapeutics can explore opportunities to expand its research and development efforts into new therapeutic areas with significant unmet medical needs. This could involve targeting diseases with limited treatment options or developing innovative therapies for emerging health challenges. The global market for pharmaceuticals is projected to reach trillions of dollars by 2028, providing ample opportunities for companies with innovative products. Timeline: Ongoing, with potential for new product launches within the next 3-5 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions can provide Inhibitor Therapeutics with access to additional resources, expertise, and distribution channels. Collaborations can also accelerate the development and commercialization of its therapeutic pipeline. The pharmaceutical industry is increasingly reliant on partnerships to share risks and leverage complementary capabilities. Timeline: Ongoing, with potential for new partnerships to be established within the next 1-2 years.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA is crucial for commercializing Inhibitor Therapeutics' products. Successful completion of clinical trials and adherence to regulatory guidelines are essential for gaining market access. The regulatory approval process can be lengthy and costly, but it is a necessary step for bringing new therapies to patients. Timeline: Dependent on the specific product and regulatory pathway, but typically takes several years.
- Out-Licensing or Sale of Assets: Inhibitor Therapeutics could explore opportunities to out-license or sell its intellectual property or specific assets to larger pharmaceutical companies. This can provide a source of non-dilutive funding and allow the company to focus on its core competencies. The market for pharmaceutical assets is active, with numerous companies seeking to acquire promising technologies. Timeline: Opportunistic, with potential for transactions to occur at any time.
- Geographic Expansion: Expanding into new geographic markets can provide Inhibitor Therapeutics with access to a larger patient population and increased revenue potential. This could involve establishing partnerships with local distributors or setting up its own sales and marketing infrastructure. The global pharmaceutical market is diverse, with significant opportunities in emerging economies. Timeline: Long-term, with potential for expansion into new markets within the next 5-10 years.
What Opportunities Does CBTE Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Securing regulatory approvals.
What Threats Does CBTE Face?
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and delays.
- Unsuccessful clinical trials.
What Are CBTE's Competitive Advantages?
- Proprietary technologies and intellectual property.
- Potential for patent protection on its therapies.
- Expertise in specific therapeutic areas.
What Does CBTE Do?
Inhibitor Therapeutics, Inc. is a pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutic solutions. While the company's founding story and specific evolution details are not provided, its core mission revolves around addressing unmet medical needs through innovative pharmaceutical products. The company's primary focus is on research and development, aiming to create proprietary therapies that can improve patient outcomes. The company's geographic reach is currently focused on the United States, with potential future expansion contingent on regulatory approvals and market opportunities. Inhibitor Therapeutics operates in a competitive landscape dominated by both large pharmaceutical corporations and smaller biotechnology firms. Its success depends on its ability to secure patents, navigate regulatory hurdles, and effectively commercialize its products. The company's business model involves significant upfront investment in research and development, followed by potential revenue generation through product sales, licensing agreements, or strategic partnerships.
What Products and Services Does CBTE Offer?
- Develops novel therapeutic solutions.
- Conducts research and development activities.
- Aims to address unmet medical needs.
- Seeks to obtain regulatory approvals for its products.
- Potentially commercializes its therapies.
- May form strategic partnerships with other companies.
How Does CBTE Make Money?
- Focuses on research and development of pharmaceutical products.
- Generates revenue through product sales, licensing agreements, or strategic partnerships.
- Requires significant upfront investment in research and development.
What Industry Does CBTE Operate In?
Inhibitor Therapeutics, Inc. operates within the medical pharmaceuticals industry, a sector characterized by intense competition, high research and development costs, and stringent regulatory requirements. The industry is driven by the constant need for innovative therapies to address unmet medical needs and improve patient outcomes. The competitive landscape includes large, established pharmaceutical companies with extensive resources and smaller, more agile biotechnology firms focused on niche markets. Inhibitor Therapeutics' success depends on its ability to differentiate itself through proprietary technologies, strategic partnerships, and efficient execution of its clinical development programs. The pharmaceutical industry is subject to evolving market trends, including the increasing demand for personalized medicine, the growing importance of biosimilars, and the rising cost of drug development.
Who Are CBTE's Key Customers?
- Patients with specific medical conditions.
- Healthcare providers who prescribe the company's therapies.
- Hospitals and clinics that administer the company's products.
Company Profile
Inhibitor Therapeutics, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Tampa, US. CBTE has traded publicly since 1997.
Key Financial Metrics
Its free cash flow yield is -22.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.3%, the inverse of the P/E and a quick read on earnings relative to price.
Net sellingInsider Activity
The most recent 12 insider filings for Inhibitor Therapeutics, Inc. break down as 3 sales and 9 purchases. On net that is roughly 2.0M shares disposed (about $3.0M), a signal worth weighing alongside the fundamentals.
CBTE Financials
Bull Case vs Bear Case
Bull Case
- Focus on innovative therapies.
- Potential for proprietary technologies.
- Dedicated research and development team.
- Upcoming: Clinical trial data releases for its therapeutic pipeline.
Bear Case
- Limited financial resources.
- Dependence on successful clinical trials.
- OTC market listing.
- Potential: Unsuccessful clinical trials.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CBTE Latest News
No recent news available for CBTE.
CBTE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBTE.
Price Targets
Wall Street price target analysis for CBTE.
CBTE MoonshotScore
What does this score mean?
The MoonshotScore rates CBTE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
CBTE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, and may be subject to heightened risks of fraud or manipulation. Trading on the OTC Other tier carries significantly less stringent listing requirements compared to major exchanges like the NYSE or NASDAQ, resulting in less transparency and regulatory oversight. Investors should exercise extreme caution when considering investments in companies trading on this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosure.
- Heightened risk of fraud or manipulation.
- Thin trading volume and wide bid-ask spreads.
- Potential for delisting or suspension of trading.
- Shell Risk Detected.
- Verify the company's management team and their track record.
- Conduct thorough research on the company's business model and industry.
- Assess the company's financial condition and ability to continue as a going concern.
- Review any available financial statements and disclosures.
- Be aware of the potential risks associated with OTC trading.
- Consult with a financial advisor before investing.
- Confirm the company's legal standing and compliance with regulations.
- Clear and transparent communication from the company.
- A well-defined business plan and strategy.
- Positive news coverage or industry recognition.
- A history of successful product development or commercialization.
- Independent audits of financial statements (if available).
CBTE Healthcare Stock FAQ
What does Inhibitor Therapeutics, Inc. do?
Inhibitor Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies. The company's business model centers around researching, developing, and potentially bringing to market new pharmaceutical products. It operates within the healthcare sector, specifically targeting medical solutions. The company aims to address unmet medical needs through its research and development efforts, seeking to create proprietary therapies that can improve patient outcomes. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
What are the main risks for CBTE?
The main risks for Inhibitor Therapeutics, Inc. include the inherent uncertainties of pharmaceutical research and development, such as the potential for unsuccessful clinical trials and regulatory delays or rejections. Competition from larger pharmaceutical companies with greater resources poses a significant threat. The company's limited financial resources and OTC market listing also present challenges. Investors should be aware of the potential for thin trading volume, wide bid-ask spreads, and limited financial disclosure associated with OTC-listed companies. Shell Risk has also been detected.
What are the key factors to evaluate for CBTE?
Evaluate CBTE on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does CBTE data refresh on this page?
CBTE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CBTE's recent stock price performance?
Inhibitor Therapeutics, Inc. (CBTE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBTE overvalued or undervalued right now?
Valuing Inhibitor Therapeutics, Inc. (CBTE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CBTE?
Before investing in Inhibitor Therapeutics, Inc. (CBTE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CBTE to a portfolio?
Key strength of Inhibitor Therapeutics, Inc. (CBTE): Focus on innovative therapies. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Inhibitor Therapeutics, Inc. due to its OTC listing and limited coverage.
- AI analysis pending for CBTE.